GE HealthCare unveils Freelium, a next-gen sealed magnet platform designed to revolutionize MR imaging with minimal helium usage.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
On Thursday, GE HealthCare GEHC reported fourth-quarter adjusted EPS of $1.45, up from $1.18 a year ago, beating the consensus of $1.26.
GE HealthCare Technologies Inc. (NASDAQ:GEHC ) Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ET Company Participants Carolynne Borders - Chief IR Officer Peter Arduini - President and CEO Jay Saccaro - VP and CFO Conference Call Participants Anthony Petrone - Mizuho Financial Group Craig Bijou - BofA Securities Vijay Kumar - Evercore ISI Matt Taylor - Jefferies Joanne Wuensch - Citi Larry Biegelsen - Wells Fargo David Roman - Goldman Sachs Robbie Marcus - JPMorgan Operator Good day, and thank you for standing by. Welcome to the GE HealthCare Fourth Quarter and Full Year 2024 Earnings Conference Call.
GEHC's fourth-quarter results reflect strength in the Advanced Visualization Solutions and Pharmaceutical Diagnostics segments. The bottom line improves on better pricing.
Medical technology and pharmaceutical diagnostics specialist GE HealthCare Technologies (GEHC -1.30%) reported mixed financial results for the fourth quarter of 2024 on Thursday, Feb. 13. Adjusted earnings per share (EPS) of $1.45 were a significant beat over the anticipated $1.27.
GE HealthCare Technologies (GEHC) came out with quarterly earnings of $1.45 per share, beating the Zacks Consensus Estimate of $1.26 per share. This compares to earnings of $1.18 per share a year ago.
GE HealthCare Technologies on Thursday forecast annual profit above Wall Street estimates, counting on strong demand for its medical devices in markets such as the U.S. to offset weakness in China.
GE HealthCare (GEHC) reported better-than-expected fourth-quarter profit on Thursday, while sales were in line with analysts' estimates.
The company said it was “pleased with
The medical imaging company issues solid guidance for 2025.
GEHC's fourth-quarter results are likely to reflect mixed segmental performance in imaging, advanced visualization solutions and patient care. Pharma is likely to have been the key driver.